Does IVIg administration yield improved immune function in very premature neonates

J. L. Wynn, P. C. Seed, C. M. Cotten

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.

Original languageEnglish (US)
Pages (from-to)635-642
Number of pages8
JournalJournal of Perinatology
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2010

Fingerprint

Intravenous Immunoglobulins
Intravenous Administration
Immune System
Gestational Age
Sepsis
Therapeutics

Keywords

  • IVIg
  • immune function
  • neonate
  • premature
  • sepsis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

@article{59d7d65fbae04809b2290c78e08be4a5,
title = "Does IVIg administration yield improved immune function in very premature neonates",
abstract = "Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.",
keywords = "IVIg, immune function, neonate, premature, sepsis",
author = "Wynn, {J. L.} and Seed, {P. C.} and Cotten, {C. M.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1038/jp.2009.197",
language = "English (US)",
volume = "30",
pages = "635--642",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "10",

}

Does IVIg administration yield improved immune function in very premature neonates. / Wynn, J. L.; Seed, P. C.; Cotten, C. M.

In: Journal of Perinatology, Vol. 30, No. 10, 01.10.2010, p. 635-642.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Does IVIg administration yield improved immune function in very premature neonates

AU - Wynn, J. L.

AU - Seed, P. C.

AU - Cotten, C. M.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.

AB - Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.

KW - IVIg

KW - immune function

KW - neonate

KW - premature

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=77957585989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957585989&partnerID=8YFLogxK

U2 - 10.1038/jp.2009.197

DO - 10.1038/jp.2009.197

M3 - Review article

C2 - 20054335

AN - SCOPUS:77957585989

VL - 30

SP - 635

EP - 642

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 10

ER -